



HEALTH ECONOMICS

PharmaLex Sweden offers an array of scientific grade services within health economics and real-world-evidence research

- Early advice on **health economics**, reimbursement and **market access strategy**.

We provide advice on content required to support **product value**, for market access, which actions to take to produce this content to **realize the full health-economic potential** of the product, and provide **recommendations** on the **timing** of these actions during the product development.

We develop **early-phase models guiding predictions** of which price level that may be justified for your product **based on available information** and the **expected outcome** of the clinical development program.

A PHARMALEX SOLUTION THAT MEETS YOUR EVOLVING NEEDS

- **Pricing and Reimbursement road map**

Some products are suitable for being included in the reimbursement scheme, others are sold on a tender basis, and some access the market via both routes. All products have their own circumstances and the systems vary between countries. We will guide you in finding the best route(s) to the market, from what is achievable and what is strategically the best choice.

- **Development of Core Value Dossiers and Core Cost-Effectiveness models**

Our team develops the full background package to support the preparation of reimbursement application dossiers in individual countries. The material includes medical, epidemiological and health-economic data as well as a cost-effectiveness model suitable for adaption to country-specific requirements.

Should Real-World Evidence beyond clinical studies be needed to support the product value, our scientific team will ensure that studies are designed and data collected to address identified data gaps.

- **Preparation of reimbursement applications in individual countries**

PharmaLex Sweden has been developing reimbursement applications for over 15 years, ever since the Pricing and Benefits Boards started to operate in the Nordic markets. As a part of PharmaLex GmbH we have expanded our services, providing similar support in additional, selected markets. In countries where we do not have in-house expertise, a network with collaborating companies will provide support.



UNIQUE
POSSIBILITIES



DEFINE UNMET
NEEDS



SUPPORT
MARKET ACCESS



COLLECT
STRATEGIC
INFORMATION

InnoPHILEX
DISCOVERY /
NON-CLINICAL

CLINICAL
DEVELOPMENT

MARKETING AUTHORIZATION
/ APPROVAL

SourcePHILEX
PRODUCT
MAINTENANCE

DELIVERING SUCCESS WITH CONFIDENCE

CONTACT US



ASA PIHLBLAD
Managing Director
PharmaLex Sweden
asa.pihlblad@pharmalex.com



Since our founding in 1994, every single one of our clients is our top priority! We lead where others follow. We help clients to go beyond compliance, to capitalize on greater efficiencies, streamline complexity and to deliver true business value.

Ask us how we can make your job easier - over 600 customers are glad they did."

Dr. Thomas Dobmeyer, CEO

PharmaLex is one of the largest specialized providers of **Development Consulting, Regulatory Affairs, Quality Management & Compliance and Pharmacovigilance, Epidemiology & Risk Management** worldwide. Our global teams of experts can take you through early strategic planning activities and non-clinical requirements to clinical development, through regulatory submission processes and finally guide you to market approval and product maintenance post-launch activities.



**KNOWLEDGE.
ACCELERATED.**
confidence beyond compliance

PharmaLex supplies the widest range of **highly-skilled leading experts**. Our experienced teams span **all geographies** to expedite product developments and provide **access to much needed resources**.

Stay **one step ahead** of essential requirements needed by health agencies worldwide. Our knowledge accelerates your business success...

Knowledge. Accelerated.

| | | |
|---|--|---|
|  <p>850+ SUBJECT MATTER EXPERTS WORLDWIDE</p> | <p>25+ YEARS OF INDUSTRY EXPERIENCE</p>  | |
| <p>9/10  TOP PHARMACEUTICAL COMPANIES ARE OUR SATISFIED CLIENTS</p> | <p> 40+ NATIONALITIES ON STAFF, INCLUDING FORMER FDA AND EMA EXPERTS</p> | <p>50+% OF OUR PROJECTS ARE GLOBAL</p>  |